Subscribe to RSS
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.4103/ijmpo.ijmpo_154_18
Octamer 4 expression and lymph node metastasis in ductal carcinoma of breast: Are they associated?
Financial support and sponsorship Nil.![](https://www.thieme-connect.de/media/10.1055-s-00050348/201901/lookinside/thumbnails/10_4103_ijmpo_ijmpo_154_18_63-1.jpg)
Abstract
Purpose: Octamer 4 (Oct-4) is a transcription factor which is required for the self-renewal and pluripotency of embryonic stem cells and germ cells. In this study, we tried to examine the association of expression of Oct-4 with lymph node metastasis in ductal carcinoma of the breast. Methods: The study was conducted on a total of 45 cases of invasive ductal carcinoma of breast, no special type. Oct-4 expression was studied on paraffin-embedded sections by immunohistochemistry. Results: Oct-4 expression was seen in 22.2% of cases. No statistically significant association was found between the expression of Oct-4 and histological type, tumor size, histological grade, and lymph node metastasis. Of Oct-4 positive tumor, 80% of cases showed lymph node metastasis, as compared to 62.85% without Oct-4 expression. However, the association was statistically insignificant. Conclusion: Oct-4 expression can be a promising biomarker of carcinogenesis, metastatic potential, and prognosis of carcinoma breast. However, the study with larger sample size is needed to establish the clinicopathological potential of this biomarker.
Publication History
Article published online:
08 June 2021
© 2019. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90
- 2 Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER, Cruz AB. et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 1983; 52: 1551-7
- 3 Saez RA, McGuire WL, Clark GM. Prognostic factors in breast cancer. Semin Surg Onco 1989; 5: 102-10
- 4 Boiani M, Schöler HR. Regulatory networks in embryo-derived pluripotent stem cells. Nat Rev Mol Cell Biol 2005; 6: 872-84
- 5 Monsef N, Soller M, Isaksson M, Abrahamsson PA, Panagopoulos I. The expression of pluripotency marker Oct 3/4 in prostate cancer and benign prostate hyperplasia. Prostate 2009; 69: 909-16
- 6 Tai MH, Chang CC, Kiupel M, Webster JD, Olson LK, Trosko JE. Oct4 expression in adult human stem cells: Evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis 2005; 26: 495-502
- 7 Niwa H, Miyazaki J, Smith AG. Quantitative expression of oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet 2000; 24: 327-6
- 8 Chavez L, Bais A, Vingron M, Lehrach H, Adjaye J, Herwig R. In silico identification of a core regulatory network of OCT4 in human embryonic stem cells using an integrated approach. BMC Genomics 2009; 10: 314
- 9 van de Geijn GJ, Hersmus R, Looijenga LH. Recent developments in testicular germ cell tumor research. Birth Defects Res C Embryo Today 2009; 87: 96-113
- 1 Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M. et al.Cancer Incidence in Five Continents. IARC Scientific Publication No-160. Vol. 9. Lyon: IARC; 2007.
- 11 Liu CG, Lu Y, Wang BB, Zhang YJ, Zhang RS, Lu Y. et al. Clinical implications of stem cell gene Oct-4 expression in breast cancer. Ann Surg 2011; 253: 1165-71
- 12 Cai S, Geng S, Jin F, Liu J, Qu C, Chen B. et al. POU5F1/Oct-4 expression in breast cancer tissue is significantly associated with non-sentinel lymph node metastasis. BMC Cancer 2016; 16: 175
- 13 Gwak JM, Kim M, Kim HJ, Jang MH, Park SY. et al. Expression of embryonal stem cell transcription factors in breast cancer: Oct4 as an indicator for poor clinical outcome and tamoxifen resistance. Oncotarget 2017; 8: 36305-18
- 14 Wang D, Lu P, Zhang H, Luo M, Zhang X, Wei X. et al. Oct-4 and nanog promote the epithelial-mesenchymal transition of breast cancer stem cells and are associated with poor prognosis in breast cancer patients. Oncotarget 2014; 5: 10803-15
- 15 Abou Gabal HH, Abu-Zeid RM, El-Maraghy MN. Implication of Oct-4 in breast carcinoma from initiation to lymph node metastasis: An Immunohistochemical study. Egypt J Pathol 2016; 36: 194-200
- 16 Hassiotou F, Hepworth AR, Beltran AS, Mathews MM, Stuebe AM, Hartmann PE. et al. Expression of the pluripotency transcription factor OCT4 in the normal and aberrant mammary gland. Front Oncol 2013; 3: 79
- 17 Madjd Z, Hashemi F, Shayanfar N, Farahani E, Zarnani AH, Sharifi AM. et al. OCT-4, an embryonic stem cell marker expressed in breast, brain and thyroid carcinomas compared to testicular carcinoma. Iran J Cancer Prev 2009; 2: 167-73